Northwestern Cancer Prevention Consortium
- ClinicalTrials.gov: A registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.
- NCPC Clinical Trials:
- NWU20-01-03 - ROLE OF LISINOPRIL IN PREVENTING THE PROGRESSION OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD): RELIEF-NAFLD (Currently Recruiting).
- NWU20-02-01 - SURGICAL WINDOW OF OPPORTUNITY STUDY OF MEGESTROL ACETATE COMPARED WITH MEGESTROL ACETATE AND METFORMIN FOR ENDOMETRIAL INTRAEPITHELIAL NEOPLASIA (Currently Recruiting).
- NWU20-02-02 - A RANDOMIZED AND PLACEBO-CONTROLLED PHASE II TRIAL TARGETING DOMINANT-NEGATIVE MISSENSE MUTANT P53 BY ATORVASTATIN FOR REDUCING THE RISK OF LONGSTANDING ULCERATIVE COLITIS-ASSOCIATED CANCER (Currently Recruiting).
- NWU20-04-01 - METFORMIN FOR CHEMOPREVENTION OF LUNG CANCER IN HIGH-RISK OVERWEIGHT OR OBESE INDIVIDUALS (Currently Recruiting).
- INT21-05-01 - A PHASE IIB CLINICAL TRIAL OF THE MULTITARGETED RECOMBINANT ADENOVIRUS 5 (CEA/MUC1/BRACHYURY) VACCINES (TRI- AD5) AND IL-15 SUPERAGONIST N-803 IN LYNCH SYNDROME (Currently Recruiting).
Please email NCPC@northwestern.edu for information about chemoprevention trials.
- Surgical window-of-opportunity study of megestrol acetate compared with megestrol acetate and metformin for endometrial intraepithelial neoplasia
- Lessons Learned from the Impact of COVID-19 on NCI-sponsored Cancer Prevention Clinical Trials: Moving Toward Participant-centric Study Designs
- A Randomized, Double-Blinded, Placebo-Controlled Trial of Simvastatin to Prevent Recurrent Pancreatitis
- Local transdermal delivery of telapristone acetate through breast skin, compared with oral treatment: a randomized double-blind, placebo-controlled Phase II trial
- A Phase I Trial of Berberine in Chinese with Ulcerative Colitis
- Phase I trial of endoxifen gel versus placebo gel in women undergoing breast surgery
- Local transdermal therapy (LTT): Drug permeation and distribution of telapristone acetate (TPA) in a pre-surgical window study of women undergoing mastectomy.
- Progesterone receptor (PR) antagonism by telapristone acetate (TPA): A randomized, placebo-controlled phase IIB pre-surgical window trial in women with stage 0-II breast cancer.
- Evaluating intermittent dosing of aspirin for colorectal cancer prevention.
- A phase IIB pre-surgical trial of oral tamoxifen (TAM) versus transdermal 4-hydroxytamoxifen (4-OHT) in women with DCIS of the breast.
- Prevention of colonic neoplasia with polyethylene glycol: a short term placebo-controlled double-blinded trial.
- Myo-inositol reduces β-catenin activation in colitis
- Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men
- Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin
- Novel routes for administering chemoprevention: Local transdermal therapy to the breasts
- Clinical Trial Laboratory Data Nested With in Subject: Components of Variance, Sample Size and Cost.
- A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast
- A phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakia
- Innovative Approaches to Tamoxifen Administration for Breast Cancer Prevention. In: Tamoxifen Concepts and Cancer New Paradigms, Chap5
- A Fitting Prescription for All: Whole Soyfoods as Part of a Varied Plant-Based Diet
- Recruitment strategy cost and impact on minority accrual to a breast cancer prevention trial
- Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial
- Prediction of menopausal status from estrogen-related gene expression in benign breast tissue
- Methyl selenocysteine: single-dose pharmacokinetics in men
- The ninth annual American association for cancer research international conference on frontiers in cancer prevention research.
- Inhibition of cancer cell invasion and metastasis by genistein
These studies are funded by a contract from the National Cancer Institute, National Institutes of Health and the U.S. Department of Health and Human Services.
For more information, review the contact information below.